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Introduction
Chondrosarcoma constitute nearly 8% of primary bone
tumors overall and 10% of them are diagnosed in the
head and neck region [1]. This type of neoplasm may
arise from cartilage, mesenchymal cells or embryonal
rests. Chondrosarcoma of the head and neck demon-
strate variable growth and their aggressiveness is
dependent on histologic grade. These tumors grow
locally with involvement of adjacent visceral and neu-
rovascular structures [2]. Regional and remote metas-
tases are uncommon. The clinical symptoms depend
upon whether neighbouring structures such as orbit,
paranasal sinuses, eustachian tube, or cranial compart-
ments are involved. Complete resection is an  initial
treatment, however local recurrence after surgery
alone is greater than 65% [3]. Radiotherapy is used as
adjuvant therapy for residual cancer, as salvage thera-
py for relapses, and prophylactically for large tumors
with negative resection margins [4], but nearly 80% of
patients die of uncontrolled local disease [3]. Some
investigators underline ineffectiveness of radiation and
chemotherapy [3,5] and on the other hand suggest that
immunotherapy against chondrosarcoma could be pos-
sible [5].
Since conventional therapies, such as surgery,
chemotherapy, and irradiation are limited, there is an
urgent need for new therapeutic approaches.
Immunotherapy with the use of DCs is becoming of
interest for different solid tumors including sarcoma.
Dendritic cells (DCs) are the most effective profes-
sional antigen presenting cells with an ability to prime
both a primary and secondary immune response to
tumor antigens. Large amounts of DCs can be generat-
ed from peripheral blood monocytes with the use of
GM-CSF and IL-4 [6] and different stimuli are used to
induce their maturation [7]. Numerous strategies are
present for loading tumor antigens into DCs. Pulsing
with synthetic peptides and genetic modification of
DCs with RNA or DNA vectors are used for well
known tumor antigens. There are also methods with
the use of whole tumor cells as a source of antigen:
tumor lysates, tumor-DC fusion techniques, acid elut-
ed peptides or apoptotic tumor cells. Several clinical
trials with the use of tumor antigens loaded dendritic
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cells were conducted in the therapy of neoplasms  [7-
11]. We present a case report of patient with intracra-
nial chondrosarcoma and attempt to use vaccination of
dendritic cells as the salvage therapy.
Materials and methods
Patient. A 55-year-old woman was admitted to Department of Oto-
laryngology and Laryngological Oncology for the diagnosis of
nasal septum tumor. The tumor filling patient's left nasal cavity
was diagnosed in 2003. The surgical resection of the tumor was
performed in March 2003. Postoperative pathomorphologic diag-
nosis was: chondroma and chondromatic infiltration of the bones.
Because of the local recurrence another surgical procedure involv-
ing: resection of the tumor with ethmoid sinuses, fundus of sphe-
noid sinus, posterior part of the palatal bone, nasal septum, left -
sided rhinotomy was performed in 2004. Postoperative pathomor-
phologic diagnose was: Chondroma in statu malignisationis/Chon-
drosarcoma - G1. After the surgical treatment was finished, the
patient was qualified for radiotherapy with Co60, with the total
dose of 6600cGy/g. The postradiation reaction I - II° was observed.
Another surgery of paranasal sinuses (ethmiod and maxillary) with
Denker's method was done in February 2005. In postoperative
histopathologic result the neoplasmatic infiltration of the skull was
described. The resection of the ethmoid sinuses and frontal cranial
fossa tumor was performed in February 2006. In June 2006 the
patient was disqualified from radiotherapy. The patient was admit-
ted to the Department of Otolarygology with a suspicion of a recur-
rence in ethmoid bones and the medial wall of the orbit in Novem-
ber 2006. The partial resection of the tumor was done and the
material for immunotherapy was taken. The immunotherapy proto-
col was approved by the Ethics Committee of the Medical Univer-
sity of Lublin and patient gave a written informed consent to the
therapy. After the procedure swelling of the left eye conjunctiva
arised and the limitation of left eyeball mobility concerning its
abduction and adduction was observed. The patient didn't complain
about diplopia, both pupils were round, equal, with proper both
side eyelids closing. The patient was admitted to the Department of
Otolarygology on 25th of  February 2007, unconscious, with spas-
tic paresis of upper and lower limbs. Very high fever up to 41.3°C
occurred.  The patient's general state was getting constantly worse.
Because of breathing problems the patient was ventilated by a res-
pirator. Fatal arrhythmia was observed. The patient died on 2nd of
March 2007. 
Dendritic cells generation. Periphral blood mononuclear cells
(PBMC) were isolated from 150 ml of peripheral blood, taken by
venipuncture, by gradient centrifugation on Gradisol L (Aqua-
Medica, Poland) and washed twice in PBS withou Ca2+ and Mg2+
(Biochrome, Germany). CD14+ monocytes were enriched by
positive selection of CD14+ cells in magnetic field according to
the manufacturer's protocols (anti-CD14 MicroBeads and Vari-
oMACS, Miltenyi-Biotec, Germany). After the isolation, CD14+
cells were washed twice in PBS and seeded into three level cell
culture flasks (Cell FactoryTM, Nunc, Denmark) in RPMI 1640
medium (Biochrome, Germany) supplemented with 2% human
albumin (ZLB Bioplasma AG, Switzerland), 100 IU/ml peni-
cillin, 50 mg/ml streptomycin and 100 mg/ml neomycin for 7
days. On days 1, 3 and 5 of the culture 1,000 IU/ml rhGM-CSF
(Leukine, Berlex, USA) and 500 IU/ml rhGM-CSF rhIL-4
(Strathmann, Germany) were added. Human tumor necrosis fac-
tor α (rhTNFα, [Strathmann, Germany]) at a concentration of 50
ng/ml and the tumor cells lysates were added during the last 48
hours of culture for the maturation and antigen loading of the
DCs. On day 8, generated dendritic cells were harvested using
Trypsin/EDTA solution (Biochrome, Gemrany), washed twice in
0.9% NaCl. Viability was checked by Trypan Blue staining in
light microscopy. Flow cytometry analysis was performed using
mouse monoclonal antibodies (mAb) against CD80, CD86,
CD83, CD1a and HLA-DR, all purchased from BDPharmingen,
USA. The vaccine product was  divided to single doses and
stored in liquid nitrogen.
Preparation of the neoplastic cells lysates. Neoplastic cells were
obtained during palliative operation. Tumor samples (without
necrotic areas) were digested with 1 mg/ml of type I collagenase
(Biochrome AG, Germany), 1 mg/ml of type I deoxyribonucleic
(Sigma, Germany) and 0.1 mg/ml of hyaluronidase (Sigma, Ger-
many) and washed twice in RPMI 1640 (Biochrome, Germany).
Tumor cells were homogenized by five repeated cycles of quick
freezing and thawing. Large particles were removed by centrifuga-
tion and after that supernatants were passed through a 0.2 μm pore
filter, the protein content was determined by OD measurement
(DU®530 spectrophotometer, BeckmanCoulter, USA) and aliquots
were stored at  -80°C until use. 100 μg/ml  protein was used for
stimulation of  DCs.
Proliferation assay. CD3+ cells were separated from the patient
peripheral blood. Magnetic labeled anti-CD3 antibodies and sepa-
ration column (Miltenyi Biotec) were used according to the manu-
facturer's instructions. Next 5×104 cells/well of CD3+ cells were
seeded in 96-well flat-bottom plates (Nunc). CD3+ lymphocytes
cultured with autologous DCs loaded with lysates (at a 20:1 ratio)
or with lysates only for 72 hours. CD3+ cells cultured seprately
were used as a negative control. CD3+ cells stimulated with PMA
(Sigma-Aldrich, Germany) were used as a positive control. 3H-
thymidine (1 μCi/well, Lecomed, Czech Republic) was added for
the last 16 hours of culture. Cells were harvested onto filter papers
with a Skatron (Lier, Norway) cell harvester. Thymidine incorpo-
ration was measured in mean counts per minute (cpm) from  trip-
licate experiments using a beta scintillation counter (Wallac 1409,
Perkin Elmer, USA).
Peripheral blood lymphocytes immunophenotyping. The per-
centages of the cells positive for the following surface antigens:
CD14/CD45, CD3/CD19/CD69, CD3/CD19/CD25, CD3/CD19/
CD95, CD4/CD8/CD69, CD4/CD8/CD25, CD4/CD8/CD95 were
examined (BD Pahrmingen, USA). The samples were collected
and measured using the FACS Calibur cytometer (Becton Dickin-
son, USA) and the data were analyzed by the CellQuestTM software
(Becton Dickinson, USA).
T regulatory cells estimation. Treg lymphocytes were estimated
by Human Treg Flow™ Kit (FOXP3 Alexa Fluor® 488/CD4 PE-
Cy5/CD25 PE, Biolegend, USA) according to the manafacturer's
protocol. Results are calculated as mean CD4+/CD25+/FOXP3+
cells percentage in CD4+ gate from triplicate counting for each
sample.
Vaccination protocol. A single dose of vaccine product was
thawed directly before vaccination. DCs vaccines were injected
intradermally in the close vicinity of cervical and nuchal lymph
nodes. Patient recived 3 doses of DCs vaccines biweekly. Due to
the progression of diseases the vaccination protocol was stopped. 
Evaluation of the clinical response and the toxicity of the DC
vaccination. Patient was checked before each vaccination by
physical examination, differential blood count and serum chem-
istry. Patients was monitored for local and systemic toxicity
according to the grading system of the National Cancer Institute
(NCI-CTC). 
Cutaneous delayed-type hypersensitivity (DTH). Simultaneous-
ly to vaccination tumor cell lysates (300 μg/ of  total  protein),
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25×104 of  loaded dendritic cells and  100 μl 0.9% NaCl  were
administered intradermally into the forearm. DTH reactivity
(induration) was measured at 72 h.
Enzyme-linked immunosorbent spot (ELISPOT) assay for
the detection of interferon gamma (IFN-γ) secretion. IFN-γ
ELISPOT assays were performed according to the manufacturer's
protocol (Mabtech, Germany) and as described earlier in detail
[13]. Briefly, 96-well nitrocellulose plates (Millipore, Germany)
were coated with INF-γ mAbs (Mabtech) and incubated
overnight at 4°C. After washing with PBS (Invitrogen Gibco,
USA), plates were blocked with 10% human AB serum (German
Red Cross Blood Bank, Ulm) for 2 h at 37°C. 5×104 CD3+ T-
lymphocytes and 1×104 target cells (tumor cells) were added to
each well. As a positive lectin control 1 µg/ml Pokeweed Mito-
gen (PWM) (Sigma-Aldrich) was used and CD3+ T lymphocytes
served as negative control. After the incubation in RMPI 1640
medium (Biochrom AG) overnight, plates were washed with
PBS. 0.2 µg/ml IFN-  mAbs (Mabtech) were added to each well,
plates were incubated for 2 h at room temperature. Cells were
washed with 1 µg/ml streptavidin-alkaline phosphatase
(Mabtech) for 2 h. Plates were washed and BCIP/NBT (5-bromo-
4-chloro-3-indolyl phosphate p-toluidine / nitroblue tetrazolium,
Sigma-Aldrich) was used for colorization according to the man-
ufacturer's instructions. 
Plates were dried up at room temperature and thereafter evalu-
ated by the use of an ELISPOT reader consisting of a video cam-
era and a computer system with pattern recognition software (CTL,
Germany). 
Granzyme B ELISPOT assay. The granzyme B ELISPOT assay
was performed as described elsewhere [14] to determine specific
lysis of target cells according to the manufacturer's instructions
(BectonDickinson, USA). 
Results
Generation of dendritic cells
From 150 ml of peripheral blood 70×106 of CD14+
monocytes were isolated and after 7-days culture
20×106 of moDC was harvested. Cells were divided
into 3 doses (1st - boost dose 10×106, 2nd and 3rd both
5×106) and stored in liquid nitrogen. The harvested
cells express typical moDC morphology and
immunophenotype (Table 1). Generated dendritic cells
were able to stimulate proliferation of CD3+ lympho-
cytes (Fig. 1).
Cutaneous delayed-type hypersensitivity (DTH)
There was no positive cutaneous DTH reaction to
autologuos tumor cells lysates or moDC loaded with
lysates after any of vaccinations.
Evaluation of the clinical response 
and the toxicity of the DC vaccination
All 3 vaccinations were well tolerated and no severe
side effects were associated with the intradermal injec-
tions of pulsed DCs. Immunotherapy with allogeneic
DCs stimulated with tumor cell lysates in this case was
demonstrated to be feasible, safe and well tolerated.
During the first month of therapy patient reported the
improvement  in the quality of life and the local symp-
toms of tumor growth were not present.  During the
monthly break between 3rd and 4th vaccination the
patient's general state was getting constantly worse, that
made 4th vaccination impossible due to neurological
state. Because of breathing problems the patient was ven-
tilated by a respirator and fatal arrhythmia was observed.
CT examination revealed massive local progression of
tumor (Fig. 2). The patient died on 74th day from the first
vaccination. 
Peripheral blood lymphocytes
We did not observe any particular changes except con-
tinuous increase in CD8+/CD25+ lymphocytes during
vaccination (Fig. 3).
T regulatory lymphocytes estimation
We noticed that percentage of CD4+/CD25+/FOXP3+
was strongly reduced after 1st vaccination, but
increased during therapy (Fig. 4).
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Table 1. Immunophenotype of dendritic cells generated from
patient's peripheral blood CD14+ monocytes.
Fig. 1.  Lymphocytes proliferation assay. DCs used in all vaccines
were checked for ability to prime proliferation of autologuos
CD3+ cells.
Specific immune response to autologuos tumor
cells
In ELISPOT experiments we did not notice any spe-
cific INF-γ and granzyme B release against autologous
tumor cells by CD3+ lymphocytes.
Discussion
In the present work we use vaccination with tumor
lysate loaded DCs as a salvage therapy for the patient
with intracranial chondrosarcoma. Chondrosarcoma
comprise less than 15% of intracranial chondromatous
neoplasm and 0.15% of all primary intracranial tumors
and typically arise at the age between 40 and 50 with-
out any gender preference (2,14]. The radical surgical
resection is the preferred treatment of choice, but
unfortunately skull based chondrosarcoma has a strong
tendency for local recurrence, mainly due to the com-
plicatedness of complete resection. The effectiveness
of adjuvant therapy as irradiation and chemotherapy is
still under discussion [1,5]. In vitro experiments
showed that chondrosarcoma cells can be destroyed by
antigen specific lymphocytes and these results suggest
that immunotherapy directed against chondrosarcoma
cells is possible [5,15]. 
In our study we generated fully mature monocyte
derived DCs from peripheral blood of patient with
168 J. Tabarkiewicz et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(2): 168 (165-170) 
doi: 10.2478/v10042-008-0025-4
Fig. 2. CT examinations of patients before vaccination and 7 days before death of patients. Large progression of tumor mass is present.
advanced intracranial chondrosarcoma. Generated
dendritic cells were able to stimulate proliferation of
autologuos CD3+ lymphocyte. Three doses of vaccine
were injected and after that treatment was stopped due
to the progression of disease. Immunotherapy with
allogeneic DCs stimulated with tumor cell lysates in
this case was demonstrated to be feasible, safe and
well tolerated. During vaccination we did not observe
any clinical or immune response. DTH tests against
autologuos tumor lysates were negative and we also
did not find any specific cytotoxic response with the
use of ELISPOT experiments. 
In many clinical trials a fraction of vaccinated
patients developed immune response against vaccinat-
ing antigens, on the other hand in some experiments
even half of the patients did not show any signs of spe-
cific immune response [7,16]. Despite encouraging
clinical response in some trials [7,9,17] we still do not
know whether the modest clinical response was caused
by immunotherapy or they reflect patients with better
prognosis capable of eliciting efficient immune
response. Investigators involved in DC vaccinations
suffered a serious defeat when a phase III clinical trial
in patients with stage IV melanoma did not succeed to
show that DC vaccination provided an increased bene-
fit compared with standard chemotherapy [18]. 
After the first vaccination we observed strong
reduction in circulating T regulatory lymphocytes,
however their percentage was continuously increasing
during therapy. CD4+/CD25+/FOXP3+ Treg cells are
well known as immunosuppressive agents hampering
anti-tumor response and elimination of these cells
enhances immunity and effectiveness of DCs vaccina-
tions [19,20]. Failure in the maintenance of
CD4+/CD25+/FOXP3+ Treg lymphocytes on the low
level could be one of the reason of ineffectiveness of
vaccination and lack of both clinical and immune
response. 
Interestingly we noticed continuous increase in cir-
culating CD8+/CD25+ cells, which also could repre-
sent population of regulatory cells. It is well docu-
mented that CD8+/CD25+ cells, especially with
simultaneous expression of FOXP3, participate in
immunosupression [21-23]. CD8+/CD3+/FOXP3+
cells and produce transforming growth factor beta,
which is also well known as cytokine participating in
tumor immune escape. On the other hand
CD8+/CD25+ are strong inducers of Graft versus Host
Disease and Graft versus Tumor effect [24].
The effectiveness of DCs vaccination in treat-
ment of the head and neck chondrosarcoma require
further investigation and clinical trials. CD4+ and
CD8+ T regulatory cells seem to play as the agents
which influence cancer immunotherapy and inhibit
priming of effective immune response. Perhaps elim-
ination of regulatory T lymphocytes during DCs vac-
cinations is needed to enhance clinical and immune
response.
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